DelveInsight’s ‘Glioma Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline glioma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the glioma pipeline domain.
Key Takeaways from the Glioma Pipeline Report
- DelveInsight’s glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for glioma treatment.
- Leading glioma companies such as Oncoceutics, Sumitomo Pharma, AiVita Biomedical, Denovo Biopharma, BeiGene, NEONC Technologies, AstraZeneca, Erimos Pharmaceuticals, Samus Therapeutics, GlaxoSmithKline, Symphogen, BioMimetix, DNAtrix, NanoPharmaceuticals, Forma Therapeutics, Oblato, Nuvation Bio, Jiangsu Chia Tai Tianqing Pharmaceutical, Incyte Corporation, Prelude Therapeutics, Orgenesis, Midatech, PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, Beijing Pearl Biotechnology, Epitopoietic Research Corporation, SonALAsense, CNS Pharmaceuticals, Adastra Pharmaceuticals, Bexion Pharmaceuticals, Inc., Merck & Co, OncoSynergy, SystImmune, Abraxis Bioscience, Day One Biopharmaceuticals, VBL Therapeutics, Shanghai Juncell Therapeutics, Eli Lilly and Company, Erimos Pharmaceuticals, PTC therapeutics, Candel Therapeutics, Kazia Therapeutics, Nereus Pharmaceuticals, Pfizer, Actuate Therapeutics and Kintara Therapeutics, Hutchison MediPharma, Apexigen, Mundipharma EDO, Boehringer Ingelheim, Erasca, Roche, ImmVira Pharma, Polaris Group, Taiho Oncology, Black Diamond Therapeutics, Arcus Biosciences, Cortice Biosciences, Peloton Therapeutics, Inovio Pharmaceuticals, others are evaluating novel glioma treatment drugs candidate to improve the treatment landscape.
- Key glioma pipeline therapies in various stages of development include ONC 201, DSP-7888, AV-GBM-1, DB102, BGB-290, , Perillyl alcohol, Selumetinib, Terameprocol, Icapamespib, Sym004, Niraparib, ivosidenib, BMX-001, DNX-2401, fb-PMT, FT-2102, OKN-007, NUV-422, rhIL-7-hyFc, Anlotinib hydrochloride, Epacadostat, PRT811, AloCELYVIR, MTX110, SONALA-001, PTC596, Nivolumab, L19TNF, NTX-301, Mirdametinib, AB-218, PVSRIPO, PLB1001, ERC1671, Berubicin Hydrochloride, BXQ-350, TG02, Pembrolizumab, OS2966, GNC-039, ABI-009, DAY101, VB 111, Tumor Infiltrating Lymphocytes (TIL), LY2157299, PTC596 CAN-2409, CAN-3110, GDC-0084, LY3410738, PF-07799933, VAL-083, 9-ING-41, Sotigalimab , Tinostamustine, BI 907828, ERAS-801, RO7428731, C5252, ADI-PEG20, TAS2940, BDTX-1535, Sabatolimab, Afatinib, Zimberelimab, TPI 287, PT2385, INO-5401 and others.
- In June 2022, Day One announced positive initial data from the pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib. Topline results from the full FIREFLY-1 trial population are expected in Q1 2023. Day One plans to initiate a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma (pLGG), with the first patient dose expected in Q3 2022.
- In June 2022, Kintara Therapeutics announced that it received fast-track designation from FDA for dianhydrogalactitol (VAL-083) for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM). VAL-083 is a first-in-class small molecule therapeutics with a novel mechanism of action. The agent has displayed clinical activity against various cancers, including the central nervous system, ovarian, and other solid tumors.
Request a sample and discover the recent advances in glioma treatment @ Glioma Pipeline Outlook
The glioma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage glioma products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the glioma pipeline landscape.
Glioma Overview
Glioma is the most prevalent type of glial cell tumor of the central nervous system (CNS). Gliomas are infiltrative tumors that impact the brain tissue around them. Glioblastoma is the most dangerous type of brain tumor, while pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were divided into subgroups and grades based on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Like most primary brain tumors, the exact glioma causes are unknown. However, some factors may raise the chances of developing a brain tumor.
Glioma symptoms vary according to tumor type, as well as tumor size, location, and rate of growth. Headache, nausea or vomiting, memory loss, urinary incontinence, speech difficulty, and others are some common glioma symptoms are common with gliomas. Glioma diagnosis involves – medical history and a physical examination The glioma treatment is determined by the tumor’s form, size, grade, and location, as well as age, overall health, and preferences.
Learn more about the novel and emerging glioma pipeline therapies @ Glioma Clinical Trials
Glioma Pipeline Therapeutics Assessment
The glioma pipeline report proffers an integral view of the glioma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Glioma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Oral, Parenteral, Intravenous, Subcutaneous
- Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
- Therapeutics Assessment By Mechanism of Action: Dopamine D2 receptor antagonists, Dopamine D3 receptor antagonists, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, T lymphocyte stimulants, 1 Phosphatidylinositol 3 kinase inhibitors, Protein kinase C beta inhibitors, Protein-serine-threonine kinase inhibitors, Proto oncogene protein c-akt inhibitors, Immunostimulants, Isocitrate dehydrogenase 1 inhibitors, MAP kinase kinase 1 inhibitors, MAP kinase kinase 2 inhibitors, Apoptosis stimulants, BIRC5 protein inhibitors, Cdc2 kinase inhibitors, Mitosis inhibitors, Transcription factor inhibitors, Antioxidants, Sulfatase inhibitors, PRMT5 protein inhibitors, Antibody-dependent cell cytotoxicity, Raf kinase inhibitors
- Key Glioma Companies: Oncoceutics, Sumitomo Pharma, AiVita Biomedical, Denovo Biopharma, BeiGene, NEONC Technologies, AstraZeneca, Erimos Pharmaceuticals, Samus Therapeutics, GlaxoSmithKline, Symphogen, BioMimetix, DNAtrix, NanoPharmaceuticals, Forma Therapeutics, Oblato, Nuvation Bio, Jiangsu Chia Tai Tianqing Pharmaceutical, Incyte Corporation, Prelude Therapeutics, Orgenesis, Midatech, PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, Beijing Pearl Biotechnology, Epitopoietic Research Corporation, SonALAsense, CNS Pharmaceuticals, Adastra Pharmaceuticals, Bexion Pharmaceuticals, Inc., Merck & Co, OncoSynergy, SystImmune, Abraxis Bioscience, Day One Biopharmaceuticals, VBL Therapeutics, Shanghai Juncell Therapeutics, Eli Lilly and Company, Erimos Pharmaceuticals, PTC therapeutics, Candel Therapeutics, Kazia Therapeutics, Nereus Pharmaceuticals, Pfizer, Actuate Therapeutics and Kintara Therapeutics, Hutchison MediPharma, Apexigen, Mundipharma EDO, Boehringer Ingelheim, Erasca, Roche, ImmVira Pharma, Polaris Group, Taiho Oncology, Black Diamond Therapeutics, Arcus Biosciences, Cortice Biosciences, Peloton Therapeutics, Inovio Pharmaceuticals
- Key Glioma Pipeline Therapies: ONC 201, DSP-7888, AV-GBM-1, DB102, BGB-290, Perillyl alcohol, Selumetinib, Terameprocol, Icapamespib, Sym004, Niraparib, ivosidenib, BMX-001, DNX-2401, fb-PMT, FT-2102, OKN-007, NUV-422, rhIL-7-hyFc, Anlotinib hydrochloride, Epacadostat, PRT811, AloCELYVIR, MTX110, SONALA-001, PTC596, Nivolumab, L19TNF, NTX-301, Mirdametinib, AB-218, PVSRIPO, PLB1001, ERC1671, Berubicin Hydrochloride, BXQ-350, TG02, Pembrolizumab, OS2966, GNC-039, ABI-009, DAY101, VB 111, Tumor Infiltrating Lymphocytes (TIL), LY2157299, PTC596 CAN-2409, CAN-3110, GDC-0084, LY3410738, PF-07799933, VAL-083, 9-ING-41, Sotigalimab, Tinostamustine, BI 907828, ERAS-801, RO7428731, C5252, ADI-PEG20, TAS2940, BDTX-1535, Sabatolimab, Afatinib, Zimberelimab, TPI 287, PT2385, INO-5401 and others.
Dive deep into rich insights for drugs for glioma, visit @ New Drug for Glioma Treatment
Table of Content
- Introduction
- Executive Summary
- Glioma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Glioma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- VB 111: VBL Therapeutics
- Mid Stage Products (Phase II)
- ONC 201: Chimerix
- Early Stage Products (Phase I)
- Autologous tumour infiltrating lymphocytes: Shanghai Gencells Therapeutics
- Preclinical and Discovery Stage Products
- Autologous T-cell therapy: Kairos Pharma
- Inactive Products
- Glioma Key Companies
- Glioma Key Products
- Glioma- Unmet Needs
- Glioma- Market Drivers and Barriers
- Glioma- Future Perspectives and Conclusion
- Glioma Analyst Views
- Glioma Key Companies
- Appendix
For further information on the glioma pipeline therapeutics, reach out @ Glioma Drugs
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/